-
News
-
2023-06-27
Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD
Verona Pharma plc (Nasdaq: VRNA) announces the submission of a New Drug Application (“NDA”) to the US Food and Drug Administration (“FDA”) for approval of ensifentrine for the maintenance treatment of patients with chron
-
2023-05-24
Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis
Bentrio® meets primary efficacy endpoint in NASAR clinical trial in seasonal allergic rhinitis
-
2023-04-10
Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD
Verona Pharma plc (Nasdaq: VRNA) announces its development partner, Nuance Pharma, has dosed the first subject in its ENHANCE - China Phase 3 trial for the maintenance treatment of chronic obstr
-
2023-03-03
Clinical Study Demonstrates Bentrio's Superior Nasal Residence Time and Rheological Properties
Altamira Therapeutics Ltd. reported that data from a recent peer-reviewed clinical study involving Bentrio nasal spray's residence time and other rheological properties demonstrated superiority vs. a saline control
-
2023-02-14
Altamira Therapeutics to Report Bentrio Clinical Data, in House Dust Mite and Grass Pollen Allergic Rhinitis, at Feb. 25 AAAAI Annual Meeting
Altamira Therapeutics Ltd. announced that data from three clinical studies with the Company's Bentrio nasal spray in allergic rhinitis will be presented February 25, at the Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI)
-
2023-01-24
Altamira Therapeutics Provides Update on Clinical Trials with Bentrio
Altamira Therapeutics Ltd. today provided an update on the clinical trials with Bentrio® in seasonal allergic rhinitis (SAR)
- 1
Contact PR
